DNA

Angle PLC Announces Half-year Report

Interim Results for the six months ended 30 June 2024LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLYThree Large Pharma contracts secured each with…

4 months ago

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO),…

4 months ago

From Trauma to Triumph, Mason Branstrator Provides Hearing Health Inspiration, Education, and Resources to a Growing Online Community

The social media influencer relies on Signia Silk Charge&Go IX's breakthrough technology and discreet design to support his active lifestyle…

4 months ago

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

BOSTON and CHESTERFIELD, Mo., Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for…

4 months ago

Certara’s Simcyp Consortium Celebrates 25th Anniversary

The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation…

4 months ago

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –…

4 months ago

Interim Results for the Six Months Ended 30 June 2024

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued…

4 months ago

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global…

4 months ago

Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)

BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,…

4 months ago